BREAST CANCER

FDA fast tracks RPTR-1.201, a TCR bispecific immunotherapy for advanced triple-negative breast cancer, as RaPTR-101 tests safety and early efficacy.

VIKTORIA-1 shows gedatolisib plus fulvestrant, with or without palbociclib, boosts PFS after CDK4/6 therapy in PIK3CA-mutant breast cancer.

The FDA has approved the first PROTAC in any indication, supported by phase 3 VERITAC-2 data.

The FDA's ODAC voted 6-3 against camizestrant for HR+/HER2– breast cancer, citing concerns over the SERENA-6 trial design and a lack of overall survival data.

Real-world data show community oncology care links to longer survival in metastatic breast cancer and NSCLC, beating national benchmarks.

A new Bayesian statistical framework uses the residual cancer burden score to better predict long-term survival in breast cancer trials beyond binary pCR.

Bayesian modeling links residual cancer burden shifts to survival, helping neoadjuvant breast cancer trials and FDA approvals predict real benefit.

MSK researchers found that BRCA2 mutations lower the barrier for RB1 loss, causing CDK4/6 inhibitor resistance.

Afuresertib plus fulvestrant cuts progression risk in HR+/HER2– metastatic breast cancer with PI3K/AKT/PTEN alterations, with manageable safety.

NCCN adds mammogram AI risk scoring; a 1.7% five‑year cutoff now prompts earlier screening and optional MRI/ultrasound.

The DAISY trial shows that HER2DX and DNADX genomic assays can predict T-DXd response in metastatic breast cancer by measuring HER2 levels and DNA instability.

Study finds risk-reducing mastectomy in BRCA1/2 carriers significantly cuts cancer risk but offers no overall survival benefit over intensive surveillance.

Victoria Rizk, MD, explores genomic assays to refine adjuvant therapy and capture clinical real-world evidence in breast cancer care.

Phase 2 TBCRC049 trial results show tucatinib triplet therapy improves survival in HER2+ breast cancer patients with leptomeningeal metastasis.

ADCs revolutionize breast cancer care, expanding beyond HER2-positive to HER2-low tumors, reshaping early therapy—and spotlighting MRD testing as the next frontier.

Genomic assays guide adjuvant therapy in HR-positive, HER2-negative breast cancer, clarifying who benefits from chemo by age, nodal status, and risk score.

Frontline antibody-drug conjugates boost progression-free survival in metastatic triple-negative breast cancer, showing early overall survival gains and expanding options.

Data presented at ESMO Targeted Anticancer Therapies Congress 2026 support ongoing phase 3 evaluation.

New HER2+ breast cancer trials refine chemo and antibody use—cutting toxicity with de‑escalation, while escalating high‑risk patients with T‑DXd.

Breast cancer care shifts fast: ADCs reach HER2-low, neoadjuvant regimens evolve, and ctDNA MRD testing sparks 2026’s debate.

AI plus digital pathology and clinical data pinpoint HR+/HER2- early breast cancers with unexpectedly low distant recurrence, sharpening prognosis and guiding endocrine or chemo choices.

Gedatolisib plus fulvestrant, with or without palbociclib, boosts PFS in HR+/HER2− PIK3CA WT breast cancer after CDK4/6.

Tumor board insights reveal how ctDNA-guided ESR1 testing and SERENA-6 strategies may reshape HR+ metastatic breast cancer and local therapy choices.

How GLP-1 weight-loss drugs fit after breast cancer: emerging survival hints, new ESMO cautions during chemo, and smart tapering to avoid rebound.